MENU

GH Stock Guardant Health (GH, $36.15) Moving Average Convergence Divergence (MACD) Histogram turned positive on January 7, 2025

A.I.dvisor
at Tickeron.com
Loading...
GH - Guardant Health
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $36.15
Daily change: +$0.27 (+0.75%)
Daily volume: 1.9M
Capitalization: $4.5B
Industry: Medical Specialties
This is a Bullish indicator signaling GH's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 50 similar cases where GH's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

GH's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for GH turned positive on January 07, 2025. Looking at past instances where GH's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on GH as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GH advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for GH moved out of overbought territory on January 14, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for GH entered a downward trend on January 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.528) is normal, around the industry mean (23.475). P/E Ratio (0.000) is within average values for comparable stocks, (83.627). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (4.021) is also within normal values, averaging (41.274).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

View a ticker or compare two or three
GH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of diagnostic technologies to improve cancer management

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Or Nursing Services
Address
3100 Hanover Street
Phone
+1 855 698-8887
Employees
1779
Web
https://www.guardanthealth.com